Ozempic And Wegovy Showing Promise In Preventing Heart Disease Among Kidney Patients
Significant Findings in Heart Health
New research unveiled at the European Association for the Study of Diabetes annual meeting reveals that Semaglutide, the active ingredient in Ozempic and Wegovy, is effective in preventing heart problems among overweight and obese individuals, particularly those with kidney diseases. A clinical trial demonstrated a 20% reduction in heart health risk for those on semaglutide over three years.
Trial Details
In a study involving over 17,600 participants with prior cardiovascular events, semaglutide users lost an average of 9% of their body weight and experienced a 31% reduction in heart health risks. This effect was especially prominent for those with impaired kidney function.
Cardiovascular Benefits
- Semaglutide presents a considerable opportunity for improved cardiovascular health in overweight patients.
- Researchers found a safe and effective profile for semaglutide in reducing cardiovascular risks.
- Results emphasize the critical role of managing both obesity and kidney health.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.